89977-78-6

Basic information

• Product Name: ethyl 1,7-dihydro-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate
• Synonyms: ethyl 1,7-dihydro-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate;ethyl 7-oxo-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate
• CAS NO: 89977-78-6
• Molecular Formula: C₈H₈N₄O₃
• Molecular Weight: 208.17412
• Mol File: 89977-78-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 318.6°Cat760mmHg
• Flash Point: 146.5°C
• Appearance: /
• Density: 1.6g/cm³
• Vapor Pressure: 0.000356mmHg at 25°C
• Refractive Index: 1.705
• CAS DataBase Reference: ethyl 1,7-dihydro-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1,7-dihydro-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate(89977-78-6)
• EPA Substance Registry System: ethyl 1,7-dihydro-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate(89977-78-6)

Safety Data

• Hazardous Substances Data: 89977-78-6(Hazardous Substances Data)

Usage

General Description

Ethyl 1,7-dihydro-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate is a chemical compound with the molecular formula C8H10N4O3. It is a derivative of 1,2,4-triazolo[1,5-a]pyrimidine and is commonly used in pharmaceutical research and development. ethyl 1,7-dihydro-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate may possess biological activity and is a potential candidate for drug discovery, particularly in the field of antiviral and antibacterial agents. It is important for its potential use in medicinal chemistry and may have applications in the treatment of various diseases and medical conditions.

InChI:InChI=1/C8H8N4O3/c1-2-15-7(14)5-3-9-8-10-4-11-12(8)6(5)13/h3-4H,2H2,1H3,(H,9,10,11)

Upstream product

• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 61-82-5 4H-1,2,4-triazol-3-amine 
• 61-82-5 3-amino-1,2,4-triazole 

Downstream Products

• 1421702-47-7 C₁₇H₂₅N₅O₂ 

Relevant articles and documents

Design and synthesis of 1,2,4-triazolo[1,5-a]pyrimidine derivatives as PDE 4B inhibitors endowed with bronchodilator activity

A series of 1,2,4-triazolo[1,5-a]pyrimidine derivatives was designed, synthesized, and screened for their phosphodiesterase (PDE 4B) inhibitory activity and bronchodilation ability. Compound 7e showed 41.80% PDE 4B inhibition at 10 μM. Eight compounds were screened for their bronchodilator activity, where compounds 7f and 7e elicited promising bronchodilator activity with EC50 values of 18.6 and 57.1 μM, respectively, compared to theophylline (EC50 = 425 μM). Molecular docking at the PDE 4B active site revealed a binding mode and docking scores comparable to those of a reference ligand, consistent with their PDE 4B inhibition activity.

Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists

CB2 cannabinoid receptor ligands are known to be therapeutically important for the treatment of numerous diseases. Recently, we have identified the heteroaryl-4-oxopyridine/7-oxopyrimidine derivatives as highly potent and selective CB2 receptor ligands, showing that the pharmakodynamics of the new compounds was controlled by the nature of the heterocycle core. In this paper we describe the synthesis and biological evaluation of 7-oxo-4-pentyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide derivatives that led to the identification of novel CB2 receptor inverse agonists. Cyclic AMP experiments on CB2 receptors expressed in CHO cells revealed that introduction of structural modifications at position 2 of triazolopyrimidine template changes the functional activity from partial to inverse agonism. The molecular docking analysis of the novel structures is reported.